Latest breakthroughs in the treatment of breast cancerBy 2025, the domain of advanced breast cancer treatment is swiftly transforming, providing renewed optimism to patients globally. Recent advanceme...
immunotherapy
On June 12, 2025, the Food and Drug Administration approved pembrolizumab (Keytruda, Merck) for adults with advanced head and neck squamous cell carcinoma (HNSCC) that can be surgically removed and sh...
immunotherapy
IMPower133 study
The IMpower133 study has brought significant advancements in the treatment of advanced-stage small-cell lung cancer (ES-SCLC). By combining atezolizumab, a type of immunotherapy, wit...
immunotherapy
On May 15, 2025, the Food and Drug Administration sanctioned retifanlimab-dlwr (Zynyz, Incyte Corporation) in conjunction with carboplatin and paclitaxel for the initial treatment of people with inope...
immunotherapy
On April 23, 2025, the Food and Drug Administration sanctioned penpulimab-kcqx (Akeso Biopharma Co., Ltd.) in conjunction with cisplatin or carboplatin and gemcitabine for the initial treatment of peo...
immunotherapy
On December 13, 2024, the Food and Drug Administration sanctioned cosibelimab-ipdl (Unloxcyt, Checkpoint Therapeutics, Inc.), a programmed death ligand-1 (PD-L1) inhibiting antibody, for adults with...
immunotherapy
On December 4, 2024, the Food and Drug Administration sanctioned durvalumab (Imfinzi, AstraZeneca) for adults with limited-stage small cell lung cancer (LS-SCLC) whose condition remains stable after...
immunotherapy
Cancer remains one of the most challenging diseases to treat, requiring innovative and effective therapies. One of the most promising advancements in cancer treatment is Chimeric Antigen Receptor (CA...
immunotherapy
On November 8, 2024, the Food and Drug Administration sanctioned obecabtagene autoleucel (Aucatzyl, Autolus Inc.), a CD19-targeted genetically engineered autologous CAR T cell therapy, for people with...
immunotherapy
On October 3, 2024, the Food and Drug Administration sanctioned nivolumab (Opdivo, Bristol Myers Squibb Company) in conjunction with platinum-doublet chemotherapy as neoadjuvant therapy, succeeded b...
immunotherapy